Fluticasonfuroate nasal spray
Generic name
Fluticasonfuroate nasal spray
Brand name
ATC Code
R01AD12
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
In the majority of patients, fluticasone furoate is undetectable (< 10 pg/ml) after intranasal dosing of 110 micrograms once daily. Measurable levels were observed in 15.1% of children after intranasal dosing of 110 micrograms once daily and only 6.8% of children after 55 micrograms once daily. There was no evidence of higher measurable levels of fluticasone furoate in younger children (less than 6 years of age).
The following median fluticason furoate concentrations were found in subjects with measurable levels:
| Age (years) | Dose (microgram) | Concentration (pg/ml) |
| 2 to 6 | 55 | 18.4 |
| 110 | 14.3 | |
| 6 to 12 | 55 | 18.9 |
| 110 | 14.4 |
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Allergic rhinitis: furoate |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Growth inhibition
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Growth inhibition has been reported in children when therapeutic doses are used; in long-term use, especially with combined inhalation therapy for asthma, check the growth and if there is growth inhibition attempt to reduce the dose and refer to the paediatrician. The lowest possible dose must be used in children if long-term use of nasal corticosteroids in children is necessary.
Following systemic effects are possible, especially in children after using higher doses over a longer period of time: mental or behavioral changes, including psychomotor hyperactivity, insomnia, anxiety, depression, or aggression (SmPC).
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Sympathomimetics, plain | ||
|---|---|---|
| R01AA08 | ||
| R01AA05 | ||
| R01AA09 | ||
| R01AA07 | ||
| Sympathomimetics, combinations excl. corticosteroids | ||
|---|---|---|
| R01AB01 | ||
| Antiallergic agents, excl. corticosteroids | ||
|---|---|---|
| R01AC03 | ||
| R01AC01 | ||
| R01AC02 | ||
| Corticosteroids | ||
|---|---|---|
| R01AD58 | ||
| R01AD01 | ||
| R01AD05 | ||
| R01AD08 | ||
| R01AD12 | ||
| R01AD09 | ||
| R01AD59 | ||
| R01AD11 | ||
| Other nasal preparations | ||
|---|---|---|
| R01AX10 | ||
| OTHER NASAL PREPARATIONS | ||
|---|---|---|
| R01AX10 | ||
References
- Glaxo Group Ltd,, SmPC Avamys (EU/1/07/434/001-3) 11 jan 2008, www.geneesmiddeleninformatiebank.nl
- GlaxoSmithKline, Product Information Veramyst (USA), www.accessdata.fda.gov
Changes
Therapeutic Drug Monitoring
Overdose
